Astrana Ptb Ratio vs Capex To Revenue Analysis
ASTH Stock | 43.21 1.60 3.57% |
Astrana Health financial indicator trend analysis is way more than just evaluating Astrana Health prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Astrana Health is a good investment. Please check the relationship between Astrana Health Ptb Ratio and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astrana Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Astrana Stock please use our How to Invest in Astrana Health guide.
Ptb Ratio vs Capex To Revenue
Ptb Ratio vs Capex To Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Astrana Health Ptb Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Astrana Health's Ptb Ratio and Capex To Revenue is 0.11. Overlapping area represents the amount of variation of Ptb Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Astrana Health, assuming nothing else is changed. The correlation between historical values of Astrana Health's Ptb Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ptb Ratio of Astrana Health are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ptb Ratio i.e., Astrana Health's Ptb Ratio and Capex To Revenue go up and down completely randomly.
Correlation Coefficient | 0.11 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most indicators from Astrana Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Astrana Health current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astrana Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Astrana Stock please use our How to Invest in Astrana Health guide.The Astrana Health's current Selling General Administrative is estimated to increase to about 118.2 M, while Tax Provision is projected to decrease to under 22.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 596.1M | 944.7M | 1.2B | 1.2B | Total Revenue | 773.9M | 1.1B | 1.4B | 1.5B |
Astrana Health fundamental ratios Correlations
Click cells to compare fundamentals
Astrana Health Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Astrana Health fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 728.7M | 817.5M | 867.4M | 966.2M | 933.4M | 980.0M | |
Other Current Liab | 77.0M | 74.1M | 88.5M | 128.5M | 184.1M | 193.3M | |
Total Current Liabilities | 105.4M | 115.0M | 114.7M | 148.6M | 218.7M | 229.6M | |
Total Stockholder Equity | 191.5M | 330.8M | 448.2M | 542.6M | 614.2M | 644.9M | |
Net Debt | 153.3M | 67.1M | (32.1M) | (58.7M) | 27.2M | 28.6M | |
Retained Earnings | 31.9M | 69.8M | 137.2M | 182.4M | 243.1M | 255.3M | |
Accounts Payable | 6.9M | 9.6M | 5.5M | 10.5M | 9.1M | 9.5M | |
Cash | 103.3M | 193.5M | 233.1M | 288.0M | 293.8M | 308.5M | |
Cash And Short Term Investments | 219.8M | 261.2M | 286.5M | 293.6M | 296.3M | 311.1M | |
Common Stock Total Equity | 35.9K | 42K | 45K | 47K | 54.1K | 30.0K | |
Common Stock Shares Outstanding | 36.4M | 37.4M | 45.4M | 45.6M | 47.1M | 49.4M | |
Liabilities And Stockholders Equity | 728.7M | 817.5M | 867.4M | 966.2M | 933.4M | 980.0M | |
Non Current Liabilities Total | 262.2M | 257.3M | 242M | 259.1M | 303.9M | 319.1M | |
Other Stockholder Equity | 159.6M | 261.0M | 310.9M | 360.1M | 371.0M | 389.6M | |
Total Liab | 367.7M | 372.3M | 356.7M | 407.7M | 522.6M | 548.7M | |
Total Current Assets | 329.1M | 338.6M | 404.5M | 428.1M | 461.5M | 484.6M | |
Common Stock | 35.9K | 42K | 45K | 47K | 54.1K | 33.4K | |
Short Long Term Debt Total | 256.6M | 260.6M | 201.0M | 229.4M | 321.0M | 337.1M | |
Short Term Debt | 12.6M | 14.2M | 3.9M | 4.8M | 24.8M | 26.0M | |
Property Plant And Equipment Net | 26.4M | 48.5M | 68.6M | 129.0M | 44.6M | 23.8M | |
Non Current Assets Total | 399.6M | 478.9M | 462.9M | 538.1M | 471.9M | 495.4M | |
Non Currrent Assets Other | 1.7M | 19.4M | 5.9M | 4.6M | 44.6M | 46.9M | |
Net Receivables | 99.0M | 60.6M | 99.3M | 119.7M | 147.8M | 155.1M | |
Other Current Assets | 10.3M | 16.8M | 18.6M | 14.8M | 17.5M | 18.3M | |
Property Plant And Equipment Gross | 26.4M | 48.5M | 68.6M | 129.0M | 67.4M | 70.8M | |
Net Tangible Assets | 18.8M | 119.0M | 118.7M | 214.0M | 246.1M | 258.4M | |
Current Deferred Revenue | 8.9M | 13.0M | 16.8M | 531K | 744K | 706.8K | |
Noncontrolling Interest In Consolidated Entity | 786.2K | 87K | 5.9M | 2.2M | 2.5M | 1.8M | |
Other Assets | 2.4M | 55.3M | 6.5M | 6.1M | 22.1M | 12.9M | |
Long Term Debt | 232.2M | 230.2M | 182.9M | 203.4M | 258.9M | 271.9M | |
Good Will | 238.5M | 239.1M | 246.4M | 269.1M | 278.8M | 139.8M | |
Retained Earnings Total Equity | 31.9M | 69.8M | 143.6M | 192.7M | 221.6M | 232.7M | |
Short Term Investments | 116.5M | 67.7M | 53.4M | 5.6M | 2.5M | 2.4M | |
Long Term Debt Total | 232.2M | 230.2M | 182.9M | 203.4M | 233.9M | 245.6M | |
Capital Surpluse | 159.6M | 261.0M | 310.9M | 360.1M | 414.1M | 434.8M | |
Deferred Long Term Liab | 18.3M | 11.0M | 9.1M | 3.0M | 3.5M | 6.8M | |
Intangible Assets | 103.0M | 87.0M | 82.8M | 76.9M | 71.6M | 56.4M |
Currently Active Assets on Macroaxis
When determining whether Astrana Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Astrana Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrana Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrana Health Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astrana Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Astrana Stock please use our How to Invest in Astrana Health guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astrana Health. If investors know Astrana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astrana Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share 1.3 | Revenue Per Share 36.415 | Quarterly Revenue Growth 0.375 | Return On Assets 0.0449 |
The market value of Astrana Health is measured differently than its book value, which is the value of Astrana that is recorded on the company's balance sheet. Investors also form their own opinion of Astrana Health's value that differs from its market value or its book value, called intrinsic value, which is Astrana Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astrana Health's market value can be influenced by many factors that don't directly affect Astrana Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astrana Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Astrana Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astrana Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.